Invention Grant
- Patent Title: Extended dicer substrate agents and methods for the specific inhibition of gene expression
-
Application No.: US17836458Application Date: 2022-06-09
-
Publication No.: US12077756B2Publication Date: 2024-09-03
- Inventor: Bob Dale Brown
- Applicant: Dicerna Pharmaceuticals, Inc.
- Applicant Address: US MA Lexington
- Assignee: DICERNA PHARMACEUTICALS, INC.
- Current Assignee: DICERNA PHARMACEUTICALS, INC.
- Current Assignee Address: US MA Lexington
- Agency: MH2 TECHNOLOGY LAW GROUP, LLP
- The original application number of the division: US12824011 2010.06.25
- Main IPC: C07H21/02
- IPC: C07H21/02 ; A61K31/713 ; C12N15/11 ; C12N15/113

Abstract:
The invention provides compositions and methods for reducing expression of a target gene in a cell, involving contacting a cell with an isolated double stranded nucleic acid (dsNA) in an amount effective to reduce expression of a target gene in a cell. The dsNAs of the invention possess a single stranded extension (in most embodiments, the single stranded extension comprises at least one modified nucleotide and/or phosphate back bone modification). Such single stranded extended Dicer-substrate siRNAs (DsiRNAs) were demonstrated to be effective RNA inhibitory agents compared to corresponding double stranded DsiRNAs.
Public/Granted literature
- US20220315925A1 EXTENDED DICER SUBSTRATE AGENTS AND METHODS FOR THE SPECIFIC INHIBITION OF GENE EXPRESSION Public/Granted day:2022-10-06
Information query